Ayala Pharmaceuticals Inc. (ADXS)
OTCMKTS: ADXS · Delayed Price · USD
0.700
-0.010 (-1.41%)
Mar 27, 2024, 1:26 PM EDT - Market closed
Company Description
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers.
The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Ayala Pharmaceuticals Inc.
Country | United States |
Founded | 2002 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 14 |
CEO | Dr. Ruth Ben Yakar Ph.D. |
Contact Details
Address: 9 Deer Park Drive, Suite K-1 Monmouth Junction, New Jersey 08852 United States | |
Phone | 732 545 1590 |
Website | advaxis.com |
Stock Details
Ticker Symbol | ADXS |
Exchange | OTCMKTS |
Fiscal Year | November - October |
Reporting Currency | USD |
CIK Code | 0001100397 |
CUSIP Number | 007624307 |
ISIN Number | US0076244062 |
Employer ID | 84-1521955 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Ruth Ben Yakar Ph.D. | Chief Executive Officer |
Dr. Stela Gangrenovitch Ph.D. | Co-Founder, Chief Scientist Officer and Director |
Mark Gengrinovitch LLB | Co-Founder, Chief Financial Officer and Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 5, 2024 | 8-K | Current Report |
Mar 5, 2024 | DEFM14C | Filing |
Feb 23, 2024 | 8-K | Current Report |
Feb 20, 2024 | PREM14C | Filing |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | 8-K | Current Report |
Feb 6, 2024 | 8-K | Current Report |
Jan 3, 2024 | 8-K/A | [Amend] Current report |